Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AgfiledCriticalSchering Ag
Publication of PE20011093A1publicationCriticalpatent/PE20011093A1/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE PROGESTINA CON PROPIEDADES ANDROGENICAS COMO ESTROGENICAS TAL COMO NORETISTERONA (NET) O SUS DERIVADOS COMO ESTERES CARBOXILICOS. LA DOSIS DE NET ES DE 1 mg A 10mg Y LA DOSIS DURANTE 6 SEMANAS ES DE 100mg A 500mg. LA PROGESTINA SUPRIME LA ESPERMATOGENESIS E INDUCE LA OLIGOZOOSPERMIA O LA AZOOSPERMIA . LA PROGESTINA SE ADMINISTRA EN CANTIDADES SUFICIENTES COMO PARA DISMINUIR LA CONCENTRACION DEL ESPERMA EN MENOS DE 3 MILLONES/ml Y MANTENER LOS NIVELES POR LO MENOS UNA SEMANA. LA FORMULACION ANTICONCEPTIVA MASCULINA SUPRIME LA ESPERMATOGENESIS Y ES UTIL PARA PREVENIR LA CONCEPCION MASCULINAIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES PROGESTIN WITH ANDROGENIC AND ESTROGENIC PROPERTIES SUCH AS NORETISTERONE (NET) OR ITS DERIVATIVES AS CARBOXYL ESTERS. THE DOSE OF NET IS FROM 1mg TO 10mg AND THE DOSE FOR 6 WEEKS IS FROM 100mg TO 500mg. PROGESTIN SUPPRESSES SPERMATOGENESIS AND INDUCES OLIGOZOOSPERMIA OR AZOOSPERMIA. PROGESTIN IS ADMINISTERED IN SUFFICIENT AMOUNTS TO REDUCE THE CONCENTRATION OF THE SPERM TO LESS THAN 3 MILLION / mL AND MAINTAIN THE LEVELS FOR AT LEAST ONE WEEK. MALE CONTRACEPTIVE FORMULATION SUPPRESSES SPERMATOGENESIS AND IS USEFUL TO PREVENT MALE CONCEPTION
PE2001000152A2000-02-152001-02-12
MALE CONTRACEPTIVE FORMULATION INCLUDING NORETISTERONE
PE20011093A1
(en)
DERIVATIVES OF 2H-PIRIDAZIN-3-ONA, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND A PROCESS FOR THE PREPARATION OF SUCH DERIVATIVES AND THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF A PHARMACEUTICAL COMPOSITION
17ALFA - FLUOROSTEROIDS WITH INHIBITING ACTIVITY OF 5 ALFA-REDUCTASA; PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE IN THE PREPARATION OF MEDICINES FOR THE TREATMENT OF CANCER DISEASES INFLUENCED BY ANDROGENS.